ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • meta-analysis
  • meta-analysis and adverse events
  • meta-analysis and Biologic agents
  • meta-analysis and drug safety
  • meta-analysis and gout
  • meta-analysis and methotrexate (MTX)
  • meta-analysis and morbidity and mortality
  • meta-analysis and muscle strength
  • meta-analysis and ocular involvement
  • meta-analysis and osteoarthritis
  • meta-analysis and osteoporosis
  • meta-analysis and pain
  • meta-analysis and pain management
  • meta-analysis and pediatric rheumatology
  • meta-analysis and polymorphism
  • Meta-analysis and polymyalgia rheumatica
  • meta-analysis and pregnancy
  • meta-analysis and prognostic factors
  • meta-analysis and psoriatic arthritis
  • meta-analysis and pulmonary complications
  • meta-analysis and radiography
  • meta-analysis and reactive arthritis
  • meta-analysis and rheumatoid arthritis
  • meta-analysis and rheumatoid arthritis (RA)
  • meta-analysis and safety
  • meta-analysis and spondylarthritis
  • meta-analysis and spondylarthropathy
  • meta-analysis and systemic lupus erythematosus (SLE)
  • meta-analysis and systemic sclerosis
  • meta-analysis and temporal arteritis
  • meta-analysis and thrombocytopenia
  • meta-analysis and thrombosis
  • meta-analysis and tocilizumab
  • meta-analysis and total joint replacement
  • meta-analysis and treatment
  • Meta-analysis and treatment options
  • meta-analysis and uric acid
  • meta-analysis and vasculitis
  • Metabolic Crystal
  • metabolic syndrome
  • metabolic syndrome and morbidity and mortality
  • metabolic syndrome and obesity
  • metabolic syndrome and osteoarthritis
  • metabolic syndrome and prevention
  • Metabolic syndrome and psoriatic arthritis
  • Metabolic syndrome and rheumatoid arthritis
  • metabolic syndrome and rheumatoid arthritis (RA)
  • metabolic syndrome and small fiber neuropathy
  • metabolic syndrome and systemic lupus erythematosus (SLE)
  • Metabolic syndrome and systemic sclerosis
  • metabolic syndrome and therapeutic targeting
  • metabolic syndrome and thrombosis
  • metabolic syndrome and uric acid
  • metabolic syndrome and young adults
  • Metabolism
  • metabolism and bioinformatics
  • metabolism and endosomal trafficking
  • metabolism and glycolysis
  • metabolism and hepatitis
  • metabolism and lipids
  • metabolism and metabolomics
  • metabolism and mitochondria
  • metabolism and muscle
  • metabolism and osteoarthritis
  • metabolism and pharmacokinetics
  • metabolism and phenotypes
  • metabolism and rheumatic disease
  • metabolism and rheumatoid arthritis
  • metabolism and rheumatoid arthritis (RA)
  • metabolism and synovial cells
  • metabolism and toll-like receptors
  • metabolism and treatment
  • metabolomics
  • metabolomics and NETosis
  • metabolomics and osteoarthritis
  • metabolomics and psoriatic arthritis
  • metabolomics and rheumatic disease
  • metabolomics and rheumatoid arthritis
  • metabolomics and rheumatoid arthritis (RA)
  • metabolomics and symptoms
  • metabolomics and synovial fluid
  • metabolomics and systemic lupus erythematosus (SLE)
  • metabolomics and systemic sclerosis
  • metabolomics and takayasu arteritis
  • metabolomics and Urinary Biomarkers
  • metabolomics and vasculitis
  • Metalloproteinase
  • methotrexate
  • methotrexate (MTX)
  • methotrexate (MTX) and 18FDG PET/CT scan
  • methotrexate (MTX) and anti-TNF therapy
  • methotrexate (MTX) and C-reactive protein (CRP)
  • methotrexate (MTX) and clinical trials
  • methotrexate (MTX) and disability
  • methotrexate (MTX) and Disease Activity
  • methotrexate (MTX) and DMARDs
  • methotrexate (MTX) and drug therapy
  • methotrexate (MTX) and Early Rheumatoid Arthritis
  • methotrexate (MTX) and economics
  • methotrexate (MTX) and liver toxicity
  • methotrexate (MTX) and methylation
  • methotrexate (MTX) and mouse model
  • methotrexate (MTX) and neutrophils
  • methotrexate (MTX) and nursing roles
  • methotrexate (MTX) and osteoclasts
  • methotrexate (MTX) and outcome measures
  • methotrexate (MTX) and outcomes
  • methotrexate (MTX) and patient-reported outcome measures
  • methotrexate (MTX) and pediatric rheumatology
  • methotrexate (MTX) and pediatrics
  • methotrexate (MTX) and pharmacists
  • methotrexate (MTX) and pharmacokinetics
  • Methotrexate (MTX) and pharmacology
  • methotrexate (MTX) and polymorphism
  • Methotrexate (MTX) and polymyalgia rheumatica
  • methotrexate (MTX) and prednisolone
  • methotrexate (MTX) and pregnancy
  • methotrexate (MTX) and prognostic factors
  • methotrexate (MTX) and prostaglandins
  • methotrexate (MTX) and psoriatic arthritis
  • methotrexate (MTX) and psychological well-being
  • methotrexate (MTX) and qualitative
  • Methotrexate (MTX) and quality improvement
  • methotrexate (MTX) and radiography
  • methotrexate (MTX) and registries
  • methotrexate (MTX) and registry
  • methotrexate (MTX) and remission
  • methotrexate (MTX) and rheumatic disease
  • methotrexate (MTX) and rheumatoid arthritis
  • methotrexate (MTX) and rheumatoid arthritis (RA)
  • methotrexate (MTX) and risk
  • Methotrexate (MTX) and sex bias
  • methotrexate (MTX) and spondylarthritis
  • methotrexate (MTX) and spondylarthropathy
  • methotrexate (MTX) and systemic lupus erythematosus (SLE)
  • methotrexate (MTX) and therapy
  • Methotrexate (MTX) and tofacitinib
  • methotrexate (MTX) and tolerance
  • methotrexate (MTX) and treatment
  • methotrexate (MTX) and treatment guidlelines
  • methotrexate (MTX) and tumor necrosis factor (TNF)
  • methotrexate (MTX) and uveitis
  • methotrexate (MTX) and vaccines
  • methotrexate (MTX) and vasculitis
  • methotrexate (MTX) and viruses
  • methotrexate (MTX) and vitamins
  • Methotrexate and gene expression
  • methylation
  • methylation and methyltransferase
  • methylation and microbiome
  • methylation and neonatal disorders
  • methylation and osteoarthritis
  • methylation and pilot study
  • Methylation and proteomics
  • methylation and psoriatic arthritis
  • methylation and rheumatoid arthritis (RA)
  • methylation and systemic lupus erythematosus (SLE)
  • methylation and systemic sclerosis
  • methylation and transcriptional regulation
  • methylation and tumor necrosis factor (TNF)
  • MHealth
  • mHealth and healthcare management
  • mHealth and osteoarthritis
  • mHealth and rheumatoid arthritis (RA)
  • Micro-RNA
  • microarray
  • microarray assay and Gene Expression
  • microbe
  • microbiome
  • microbiome and bioinformatics
  • microbiome and connective tissue diseases
  • microbiome and Diagnostic Tests
  • microbiome and gastrointestinal complications
  • microbiome and gut
  • microbiome and interferons
  • microbiome and molecular mimicry
  • microbiome and mouse model
  • microbiome and mucosal T cells
  • microbiome and nephritis
  • microbiome and nutrition
  • microbiome and oral
  • microbiome and osteoarthritis
  • microbiome and pathogenesis
  • microbiome and patient questionnaires
  • microbiome and polyarthritis
  • microbiome and psoriatic arthritis
  • Microbiome and rheumatoid arthritis
  • microbiome and rheumatoid arthritis (RA)
  • microbiome and spondylarthritis
  • microbiome and spondylarthropathy
  • microbiome and systemic sclerosis
  • microbiome and temporal arteritis
  • microbiome and toll-like receptors
  • microbiome and transcription factor
  • microbiome and treatment
  • microbiome and tumor necrosis factor (TNF)
  • microbiome and uric acid
  • microbiome and vasculitis
  • Microchimerism
  • Microchimerism and systemic sclerosis
  • First |
  • « Previous Page
  • 34
  • 35
  • 36
  • 37
  • 38
  • [39]
  • 40
  • 41
  • 42
  • 43
  • 44
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology